Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

Female (37) experiencing hair loss for 5 years, tried max dose of spiro and oral + topical minox without success. Discovered low cortisol and low DHEA levels, seeking functional medicine practitioner for help.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The conversation discusses a comprehensive hair regrowth regimen including Dutasteride, Finasteride, microneedling, RU58841, oral and topical Minoxidil, Tretinoin, and Vitamin D3. Suggestions include dropping Finasteride, increasing Dutasteride, and considering additional treatments like caffeine, melatonin, and laser therapy, while emphasizing the effectiveness of Dutasteride and Minoxidil.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

A 21-year-old with a family history of early balding is advised to see a dermatologist to confirm androgenetic alopecia (AGA) and consider treatments like finasteride or dutasteride to prevent further hair loss, and minoxidil, possibly with tretinoin, to regrow hair. Caution is advised with oral minoxidil, and a cardiologist should be consulted before use.

A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.

A hair transplant experienced by FC Barcelona goalkeeper Ter Stegen, who reportedly saw improved confidence and performance following the procedure. People discussed finasteride as an alternative treatment option for those unable to afford a transplant.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

Best future hair loss treatment discussed: verteporfin, kx-826, and GT20029. Verteporfin could potentially end baldness with scarless procedures.

The user has been using a strong combination of hair loss treatments for 16 months, including Finasteride, Minoxidil, Dutasteride, and RU-58841, but their hair loss has worsened. They're questioning whether their high testosterone levels or residual scalp DHT are causing further hair loss, with a reply suggesting that even small amounts of DHT can cause hair loss if one is sensitive to it.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

The user is using a comprehensive hair loss treatment including oral dutasteride, minoxidil (both oral and topical), topical finasteride, RU58841, ketoconazole shampoo, and a derma roller, while also using anabolic steroids. Opinions vary, with some users noting stability or slight improvement, while others suggest the treatment may not be effective due to anabolic use.

The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.